

NEAL P. DUNN, MD
2ND DISTRICT, FLORIDA

COMMITTEE ON AGRICULTURE
COMMITTEE ON VETERANS' AFFAIRS
COMMITTEE ON SCIENCE,
SPACE, AND TECHNOLOGY

Congress of the United States
House of Representatives
Washington, DC 20515-0902

840 WEST 11TH STREET
SUITE 2250
PANAMA CITY, FL 32401
(850) 785-0812

300 SOUTH ADAMS STREET
TALLAHASSEE, FL 32301
(850) 891-8610

423 CANNON HOUSE OFFICE BUILDING
WASHINGTON, DC 20515
(202) 225-5235

October 17, 2017

Secretary Sonny Perdue
Department of Agriculture
1400 Independence Ave., S.W.
Washington, DC 20250

Administrator Scott Pruitt
Environmental Protection Agency
1200 Pennsylvania Ave NW
Washington, DC 20004

Commissioner Scott Gottlieb
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

Dear Secretary Perdue, Administrator Pruitt, and Commissioner Gottlieb,

Advances in agricultural biotechnology provide enormous potential to address some of society's most difficult challenges. Biotechnology and emerging technologies such as gene editing can enhance environmental stewardship, help manage pests and diseases like Zika and citrus greening, and aid in the reduction of hunger, food waste, and nutritional insufficiencies. It is vital, however, that these tools have a consistent, science-based, risk-proportionate regulatory system, and that we remove any unnecessary burdens that would inhibit the use of these innovative solutions.


As your agencies continue to engage in the Interagency Taskforce on Agriculture and Rural Prosperity and explore other regulatory improvement opportunities, we believe there are several recent biotechnology regulatory efforts that warrant your attention. On January 19, 2017, the U.S. Department of Agriculture's (USDA) Animal Plant and Health Inspection Service (APHIS) published a draft revision to its Part 340 biotechnology regulations. The U.S. Food and Drug Administration (FDA) proposed expanding the scope of its guidance for industry (GFI) #187 to regulate any animal intentionally altered using gene editing techniques as a new animal drug. While we appreciate the thoughtful, science-based direction USDA offers on products of biotechnology and gene editing that APHIS has ample experience regulating, we are concerned that these drafts offer deeply conflicting regulatory approaches. Moreover, we do not believe they provide the consistent, appropriate system needed to promote the development of these innovative tools.

These contradictory proposals have sent inconsistent signals to our trade partners, who are in the midst of determining their own approaches to these technologies. We are concerned that if the Administration does not quickly develop a uniform position on biotechnology in agriculture, including gene editing, we will see an unworkable patchwork of international regulations emerge that will effectively further suppress American innovation and the solutions that come with it.

We urge you to coordinate with each other and stakeholders to improve these regulatory proposals in ways that are consistent and foster innovation. We also request that you increase engagement with our trading partners to promote a harmonized, science-based international regulatory system for these products. Finally, as you consider ways to engage with the public to discuss the continued advancement of biotechnology in agriculture, recall that Congress provided \$3 million in FY17 for FDA and USDA for these purposes, which would aid engagement efforts.

We appreciate your work and attention to this critical issue, and stand ready to assist you in efforts to improve the regulatory climate so that our economy and society may benefit from these promising technologies.


Sincerely,



Neal P. Dunn, M.D.



K. Michael Conaway



Glenn 'GT' Thompson



Frank D. Lucas



Mike Rogers



Austin Scott




Jimmy Panetta




Collin C. Peterson




Bob Goodlatte




Steve King



Bob Gibbs



Rick Crawford



Scott DesJarlais

Vicky Hartzler
Vicky Hartzler



Jeff Benham

Doug LaMalfa
Doug LaMalfa

Rodney Davis
Rodney Davis

Ted S. Yoho
Ted Yoho, D.V.M.

Rick W. Allen
Rick Allen

Mike Bost
Mike Bost

David Rouzer
David Rouzer

Ralph Abraham
Ralph Abraham

Trent Kelly
Trent Kelly

James Comer
James Comer

Roger W. Marshall
Roger Marshall, M.D.

Don Bacon
Don Bacon

John Faso
John Faso

Rodney Arrington
Rodney Arrington

David Scott
David Scott

Jim Costa
Jim Costa

Timothy J. Walz
Timothy J. Walz

Filemon Vela
Filemon Vela

Michelle Lujan Grisham

Michelle Lujan Grisham

Rick Nolan

Rick Nolan

Alma Adams

Alma Adams

Al Lawson, Jr.

Al Lawson, Jr.

Darren Soto

Darren Soto

Rod Blum

Rod Blum

Julia Brownley

Julia Brownley

Matt Cartwright

Matt Cartwright

Charlie Crist

Charlie Crist

Ann Kuster

Ann Kuster

Cheri Bustos

Cheri Bustos

Dwight Evans

Dwight Evans

Tom O'Halleran

Tom O'Halleran

Lisa Blunt Rochester

Lisa Blunt Rochester

Susan W. Brooks

Susan W. Brooks

Bradley Byrne


Bradley Byrne


Kevin Cramer


Kevin Cramer

Ron Estes

Ron Estes



John Garamendi


Paul Gosar, D.D.S.


Andy Harris, M.D.


Sanford D. Bishop, III


Ron Kind



Blaine Lueckemeyer



Dan Newhouse


Erik Paulsen


Thomas J. Rooney


Vicente Gonzalez



H. Morgan Griffith


George Holding



Lynn Jenkins


Mia B. Love



Betty McCollum



Kristi L. Noem



Todd Rokita



Kurt Schrader



Dave Loebsock



Kyrsten Sinema



Adrian Smith


Ann Wagner


David Young



Sean Patrick Maloney


Tom Emmer


Terri A. Sewell


David G. Valadao


Kevin Yoder


Michael K. Simpson